{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '1.', 'SYNOPSIS', 'Protocol Title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the', 'Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in', 'Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are', 'Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed', 'an Anti-CD38 Antibody (DREAMM 2)', 'Short Title: Open-label, randomized study of two doses of GSK2857916 in participants', 'with relapsed/refractory multiple myeloma who have failed prior treatment with an anti-', 'CD38 antibody.', 'Rationale: Multiple myeloma (MM) is an incurable malignancy and accounts for 1% of', 'all cancers and for 10% of all hematologic malignancies. Worldwide, approximately', '103,000 new cases are diagnosed annually, and an estimated 30,330 new cases and', '12,650 deaths will occur in the US in 2016. Despite significant advances in treatment', 'options, including hematopoietic stem cell transplant (HSCT), and novel therapies like', 'second- and third-generation proteasome inhibitors (PIs), immunomodulatory drugs', '(IMiDs), and recent addition of monoclonal antibodies (mAbs), most MM patients will', 'ultimately develop resistance to existing therapies and die of relapse.', 'One such novel therapy, daratumumab, is a human IgGk monoclonal antibody that was', 'granted first approval in the US in November 2015. Daratumumab binds with high', 'affinity to the CD38 molecule, which is highly expressed on the surface of MM cells. It', 'is believed to induce rapid tumor cell death through apoptosis, and multiple immune-', 'mediated mechanisms, including complement-dependent cytotoxicity, antibody-', 'dependent cellular phagocytosis and antibody-dependen cellular cytotoxicity.', 'Daratumumab is approved by the FDA for the treatment of MM in combination with', 'lenalidomide and dexamethasone, or bortezomib and dexamethasone in patients who', 'have received at least one prior therapy, in combination with pomalidomide and', 'dexamethasone in patients who have received at least two prior therapies including', 'lenalidomide and a proteasome inhibitor (PI), and as monotherapy for the treatment of', 'patients who have received at least three prior lines of therapy, including a PI and an', 'IMiD, or who are double-refractory to a PI and an IMiD.', 'In Europe, daratumumab is approved for the treatment of MM in combination with', 'lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of', 'patients who have received at least one prior therapy and as monotherapy for the', 'treatment of patients with relapsed and refractory MM, whose prior therapy included a PI', 'and an immunomodulatory agent and who have demonstrated disease progression on the', 'last therapy. Patients with MM who have proven refractory to daratumumab mono- and', 'combination therapy, have few treatment options available, and could benefit', 'significantly from treatment with a next-generation regimen, such as GSK2857916.', 'GSK2857916 is a humanized (IgG1) antibody-drug conjugate (ADC) which binds to', 'BCMA, a target widely expressed on malignant plasma cells in MM. The parent anti-', 'BCMA antibody is conjugated to the microtubule inhibitor, MMAF, which is released', '11']['2017N330177_04', 'CONFIDENTIAL', '205678', 'inside the malignant cell after binding and internalization of the antibody. The normal', 'function of BCMA is to promote cell survival by transduction of signals from two known', 'ligands: B-cell activating factor from the tumor necrosis factor (TNF) family', '(BAFF/BLyS), and APRIL, a proliferation-inducing ligand.', 'In addition, preclinical experiments indicate that GSK2857916 has the potential to induce', 'immunogenic cell death (ICD) in a BCMA-expressing multiple myeloma cell line.', 'Exposure of dendritic cells to tumor cells undergoing ICD induces an antigen-specific T', 'cell response, which may help to exert anti-tumor effects.', 'Preliminary clinical data from the ongoing BMA117159 study as of 26 June 2017 (n=35', 'participants treated at 3.4 mg/kg) has demonstrated an ORR of 60% [95% CI: 42.1%,', '76.1%], (complete response: 6%, very good partial response [VGPR 43%, partial', 'response [PR] 9%), with 51% of participants (N = 18/35) having deep responses of', 'VGPR or better, in heavily pretreated participants with relapsed/refractory multiple', 'myeloma (RRMM). The median duration of response (DoR) has not been achieved, the', '25th percentile for DoR is 6.7 months; the median PFS in this population was 7.9 months', '[95% CI: 3.1, NA]. The number of prior therapies ranged from 1-13 with 71% of', 'participants reporting greater than or equal to 4 prior therapies. For the 14 (40%)', 'participants who had received prior daratumumab, the ORR was 43%, (95% CI: 17.7%,', '71.1%; CR: 0, VGPR: 21%; PR: 14%).', 'In Study BMA117159, the maximum clinical benefit (ORR) was observed at the', '3.4 mg/kg dose level, but a significant number of participants required dose delays and', 'dose reductions to manage adverse events. In order to generate additional safety and', 'efficacy data at a lower dose while providing participants a chance of deriving clinical', 'benefit, the dose of 2.5 mg/kg has been selected for testing in an additional arm in this', 'study. The two-arm design with two dose levels and a futility analysis is justified for this', 'population because there is no approved comparator for the proposed treatment setting.', 'Objectives and Enppoints', 'Objectives', 'Enppoints', 'Primary Objective', 'To evaluate the clinical efficacy of 2', 'ORR, defined as the percentage of participants with a confirmed', 'doses of GSK2857916 in participants', 'partial response (PR) or better (i.e., PR, very good partial', 'with relapsed/refractory multiple', 'response [VGPR], complete response [CR] and stringent', 'myeloma.', 'complete response [sCR]), according to the 2016 International', 'Myeloma Working Group (IMWG) Response Criteria by', 'Independent Review Committee (IRC).', 'Secondary Objectives', 'To further evaluate the clinical', 'ORR, defined as the percentage of participants with a confirmed', 'measures of efficacy of GSK2857916', 'partial response (PR) or better, according to the 2016', 'in participants with RRMM', 'International Myeloma Working Group (IMWG) Response Criteria', 'by investigator assessment', 'Clinical benefit rate (CBR), defined as the percentage of', 'participants with a confirmed minimal response (MR) or better', 'according to the 2016 International Myeloma Working Group', '12']\n\n###\n\n", "completion": "END"}